Previous Close | 10.55 |
Open | 10.71 |
Bid | 7.72 x 200 |
Ask | 10.76 x 200 |
Day's Range | 10.62 - 10.88 |
52 Week Range | 7.61 - 27.48 |
Volume | |
Avg. Volume | 897,196 |
Market Cap | 1.46B |
Beta (5Y Monthly) | 0.46 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.08 |
Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.29 |
SAN FRANCISCO, May 23, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2024 Annual Meeting of Stockholders on Wednesday, May 29, 2024, at 9:00 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.
SAN FRANCISCO, May 22, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting new data from the Company’s chronic hepatitis delta and chronic hepatitis B programs have been accepted for presentation at the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy from June 5-8. This includes an oral presentation on June 8, which was originally accepted as a late-breaker poster, that will highlig
SAN FRANCISCO, May 21, 2024--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the EASL Congress has changed the Company’s Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be presented on June 8 during the annual meeting of the European Association for the Study of the Liver, EASL™ Congress 2024, taking place in Milan, Italy, June 5-8. The Company plans to host an investor conference call to discuss the new SOLSTICE data